NeuroPace (NASDAQ:NPCE – Get Rating) will be releasing its earnings data after the market closes on Thursday, August 11th. Analysts expect NeuroPace to post earnings of ($0.44) per share for the quarter. NeuroPace has set its FY 2022 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.
NeuroPace (NASDAQ:NPCE – Get Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). NeuroPace had a negative return on equity of 47.77% and a negative net margin of 85.42%. The business had revenue of $11.37 million for the quarter, compared to analyst estimates of $10.45 million. On average, analysts expect NeuroPace to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
NeuroPace Stock Down 2.4 %
NeuroPace stock opened at $5.63 on Thursday. The stock’s 50 day moving average price is $5.62 and its 200 day moving average price is $7.08. NeuroPace has a 1-year low of $4.61 and a 1-year high of $24.77. The company has a market cap of $138.53 million, a PE ratio of -3.23 and a beta of 1.54. The company has a debt-to-equity ratio of 0.80, a current ratio of 10.15 and a quick ratio of 9.48.
Analyst Ratings Changes
Institutional Trading of NeuroPace
An institutional investor recently raised its position in NeuroPace stock. Nantahala Capital Management LLC raised its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE – Get Rating) by 58.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 485,303 shares of the company’s stock after buying an additional 179,397 shares during the quarter. Nantahala Capital Management LLC owned about 1.98% of NeuroPace worth $3,984,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 77.56% of the company’s stock.
NeuroPace, Inc operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely.
- Get a free copy of the StockNews.com research report on NeuroPace (NPCE)
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Starbucks Shooting For The Moon?
- AutoNation Stock is Firing on All Pistons
- Caterpillar Falls To Strong Support Near Bottom Of Range
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.